Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …

Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …

The effects of acute sleep deprivation on β-amyloid (Aβ) clearance in the human brain have
not been documented. Here we used PET and 18F-florbetaben to measure brain Aβ burden …

Energy demand of neurons in brain that is covered by glucose supply from the blood is
ensured by glucose transporters in capillaries and brain cells. In brain, the facilitative …

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

The high prevalence of obesity is associated with an enormous medical, social, and
economic burden. The metabolic dysfunction, dyslipidaemia, and inflammation caused by …

Currently available evidence strongly supports the position that the initiating event in
Alzheimer's disease (AD) is related to abnormal processing of β-amyloid (Aβ) peptide …

Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past
four decades. Initially, computed tomography (CT) and then magnetic resonance imaging …

Effective and accurate diagnosis of Alzheimer's disease (AD), as well as its prodromal stage
(ie, mild cognitive impairment (MCI)), has attracted more and more attention recently. So far …

Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show
any effect on disease progression in clinical trials, conceivably because the AD subjects are …